GlassScriptPhysician profile
Noori Kim
NPI 1093036758
$8,535.29
in general payments reported to CMS, 2019-2025
29 companies · $4,498 in 2025
The $4,498 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2022: $23.30 · 2023: $928 · 2024: $2,868 · 2025: $4,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,027 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,027.11 |
| Education | $267.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,215.75 | 2023-2025 | Tremfya, Simponi, Stelara |
| Revance Therapeutics, INC. | $1,109.85 | 2024-2025 | Daxxify, Daxi |
| Abbvie INC. | $716.89 | 2022-2025 | |
| Lilly USA, LLC | $635.87 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $576.77 | 2024-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $496.41 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $486.39 | 2024-2025 | |
| Genzyme Corporation | $439.98 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $411.46 | 2023-2025 | Zoryve |
| Pfizer INC. | $349.08 | 2023-2025 | |
| Incyte Corporation | $281.23 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $274.61 | 2024-2025 | |
| Ucb, INC. | $271.75 | 2024-2025 | Bimzelx |
| Amgen INC. | $250.94 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $235.80 | 2024-2025 | Nemluvio, Aklief |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $228.42 | 2023-2024 | Vtama |
| Allergan, INC. | $97.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.90 | 2024-2025 | Sotyktu |
| Medtronic, INC. | $75.97 | 2024 | V-Loc 180 |
| Organon LLC | $71.17 | 2025 | Vtama |
| Leo Pharma INC. | $41.30 | 2023-2025 | Adbry |
| Botanix Sb INC | $38.84 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.47 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.22 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Alnylam Pharmaceuticals INC. | $22.59 | 2025 | Givlaari |
| Celgene Corporation | $19.98 | 2019 | |
| Journey Medical Corporation | $14.74 | 2024 | |
| Almirall LLC | $14.51 | 2024 | Seysara |
| Sandoz INC. | $14.07 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noori Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.